Truist Financial Issues a Buy Rating on BioNTech SE (BNTX)

1 day ago · In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The company’s shares closed yesterday at $112.43. Discover ...

$112.43
OFF

Truist Financial Issues A Buy Rating On BioNTech SE (BNTX)

2 weeks from now

businessinsider.com

$172
OFF

BioNTech Initiated With A Buy At Truist - Markets Insider

2 weeks from now

6 days ago · Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it was the COVID vaccine that made …

businessinsider.com

40%
OFF

Truist Rates BioNTech A Buy, Citing 40% Upside Potential With Key …

2 weeks from now

6 days ago · On Friday, Truist Securities began coverage on BioNTech shares (NASDAQ: BNTX) with a Buy rating, accompanied by a price target set at $172.00.The securities firm's analysis …

investing.com

$172
OFF

Truist Initiates BioNTech At Buy With $172 Price Target

2 weeks from now

5 days ago · BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other …

marketscreener.com

40%
OFF

Truist Rates BioNTech A Buy, Citing 40% Upside Potential With Key …

2 weeks from now

6 days ago · Truist Securities suggests that the upcoming data read-outs in 2025 could provide substantial growth opportunities for BioNTech, justifying the Buy rating. The coverage initiation …

investing.com

40%
OFF

This Biotech Stock Is An 'oncology Powerhouse' With 40% Upside, …

2 weeks from now

5 days ago · The firm's 12-month price target on the Nasdaq-traded shares of the German company is $172.

cnbc.com

$172.00
OFF

Truist Securities Starts BioNTech (BNTX) At Buy

2 weeks from now

6 days ago · Truist Securities analyst Asthika Goonewardene initiates coverage on BioNTech (NASDAQ: BNTX) with a Buy rating and a price target of $172.00.The analyst comments: …

streetinsider.com

$172
OFF

Truist Securities Initiates Coverage On BioNTech With Buy Rating ...

2 weeks from now

6 days ago · Truist Securities Initiates Coverage On BioNTech with Buy Rating, Announces Price Target of $172 ... Price Target of $172. Benzinga·01/10/2025 10:09:50. Listen to the news. …

webull.ca

40%
OFF

Truist Rates BioNTech A Buy, Citing 40% Upside Potential With Key …

2 weeks from now

6 days ago · Truist Securities suggests that the upcoming data read-outs in 2025 could provide substantial growth opportunities for BioNTech, justifying the Buy rating. The coverage initiation …

investing.com

$137.00
OFF

Goldman Sachs Sticks To Their Buy Rating For BioNTech SE (BNTX)

2 weeks from now

1 day ago · In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $137.00. The …

businessinsider.com

$172
OFF

Truist Securities Initiates Coverage On BioNTech With Buy Rating ...

2 weeks from now

6 days ago · Truist Securities analyst Asthika Goonewardene initiates coverage on BioNTech (NASDAQ:BNTX) with a Buy rating and announces Price Target of $172.

sahmcapital.com

$150.00
OFF

Bank Of America Securities Keeps Their Buy Rating On BioNTech SE …

2 weeks from now

1 day ago · Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of $150.00. The …

businessinsider.com

FAQs about Truist Financial Issues a Buy Rating on BioNTech SE (BNTX) Coupon?

Should you buy biontech (bntx)?

Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it was the COVID vaccine that made it a household name,” the analyst tells investors in a research note. ...

Should you buy biontech se - depositary receipt (bntx)?

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) with a Buy recommendation. Analyst Price Forecast Suggests 14.22% Upside As of December 23, 2024, the average one-year price target for BioNTech SE - Depositary Receipt () is $139.52/share. ...

Is biontech a good stock to buy?

HSBC boosted their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, Canaccord Genuity Group increased their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. ...

What is the price target for biontech se - depositary receipt ()?

As of December 23, 2024, the average one-year price target for BioNTech SE - Depositary Receipt () is $139.52/share. The forecasts range from a low of $100.23 to a high of $180.02. The average price target represents an increase of 14.22% from its latest reported closing price of $122.15 / share. ...

Will biontech buy bnt327/pm8002?

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Truist initiated with a Buy rating and a price target of $172. BioNTech’s oncology pipeline was previously seen as limited in value outside BNT316. ...

Should you buy biontech se (AHM)?

According to TipRanks, Ahmad has an average return of 0.8% and a 47.97% success rate on recommended stocks. Currently, the analyst consensus on BioNTech SE is a Strong Buy with an average price target of $143.99, implying a 28.07% upside from current levels. ...